Mobile

Phase III randomized, placebo controlled study of sorafenib in repeated cycles of 21 days in combination with paclitaxel/carboplatin chemotherapy in subjects with unresectable stage III or stage IV me...

Update Il y a 4 ans
Reference: EUCTR2005-000941-12

Phase III randomized, placebo controlled study of sorafenib in repeated cycles of 21 days in combination with paclitaxel/carboplatin chemotherapy in subjects with unresectable stage III or stage IV melanoma

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate progression free survival (PFS) between subjects treated with sorafenib versus placebo in combination with paclitaxel and carboplatin.

Inclusion criteria

  • unresectable, advanced Stage III or Stage IV melanoma

Links